December 3, 2018 10:49 PM
The trial, which aims to remove inaccuracies in provider directories, was announced in April.
Healthcare giants Aetna and Ascension have both joined the Synaptic Health Alliance to trial blockchain technology for improved data storage and quality.
Aetna, which is undergoing a proposed merger with pharmacy chain CVS, is one of the biggest health insurers in the US and serves an estimated 39 million people across the nation. Ascension is the largest faith-based nonprofit healthcare provider in the US and the largest Catholic health system in the world.
The Synaptic Health Alliance launched on April 2 with five members: Humana, MultiPlan, Quest Diagnostics, UnitedHealthcare, and Optum. It plans to “determine if applying blockchain technology can help ensure the most current information about healthcare providers is available.” The project description notes that insurers currently maintain their own provider directories, with inaccuracies leading to delays in payment and lost revenue. The members hope that by utilizing a blockchain-based system, they can efficiently share data and remove inaccuracies.
Nimbus-T Global GmbH (Switzerland) is focused on secure identity management and blockchain solutions for healthcare. On-boarding of patients and doctors to a new platform that will provide a security token called a Nimbus-Key, an encrypted global Identity credential that will link to other identity credentials while protecting them. As you know, your medical records are in different locations, many locations, each with a different ID and some being duplicated. Integrity of data entry into the healthcare record is critical for your own safety. Use cases for our security solutions are focused on secure on-boarding for clinical trials, hospital systems and ACOs, health plans, universities and self-insured employers.
We are working on a coming ICO for a Nimbus-T token (NT) a ERC-20 compliant token on the Ethereum platform.
Nimbus-T token and Nimbus-Key system will change healthcare delivery and payment dramatically! Peer to peer payments without an intermediary. Imagine the increased efficiency and how we can do away with “paperwork”. Image being able to tell any healthcare system or provider that you want a copy of your medical record so that you can securely store it yourself on our Nimbus-T Medical Vault?
Also, please note, Nimbus-T inc (USA) is our company developing secure identity management solutions around the Nimbus-Key Platform. We are devoted to protecting you from fraud and abuse. Your identity should always be secure and protected.
GDPR or the new EU security standards are so important and we applaud the development. We are working on a “permissions engine” that will allow for compliance of medical access to health information for clinical trials and other uses that are deemed appropriate.
We are now launching our New Nimbus-T Telegram Channel. Please join us!
A new revolution in healthcare is coming and you can be part of it.
6th & 7th June 2018 – ExCeL London – The European Oncology Convention Booth 3002
We had a great event in London and look forward to connecting with companies that expressed interest in our technology. Check out our Nimbus-T Telegram Channel:
The European Oncology Convention is Europe’s leading trade event for oncology professionals. The show has an unparalleled line-up of expert-led seminars, interactive workshops and cutting-edge exhibitors showcasing the industry’s most state-of-the-art technologies used to study and treat cancer. Visitors get the unique opportunity to not only see the latest systems and technologies shaping the future of oncology diagnosis and treatment, but can also connect with their visionary creators under one roof.Taking place at ExCeL, London on 6th & 7th June 2018, the event is completely free to attend. To book your free tickets go to: www.oncologyconvention.com or call 0117 930 4927.
Nimbus-T presents our Nimbus-Key platform that unifies the multitude of patient data across the healthcare spectrum through secure identity management and authentication empowered by blockchain.
The Nimbus-T App brings convenience for the users, better diagnostics, time and cost savings to providers, minimizes errors and prevents ID breaches.
Whereas, most IAM providers are focused on enterprise solutions, we are focused on inter-enterprise healthcare solutions that bind medical IDs with our patent pending Nimbus-Key Platform.
We are currently focused on assisting the clinical trials community with identity management, medical records aggregation, serial consents and secure prescriptions.
We are looking forward to seeing you all at this amazing event.
Photo: LoveTheWind, Getty Images
The challenge of moving from developing a product to securing paid customers is one that is familiar to every entrepreneur, including those running digital health startups. But with healthcare, there tends to be a longer sales cycle than other industries. Just as every organization has its own corporate culture and workflows to navigate, their own pace for technology adoption, integration and protocols to follow, the extra regulatory concerns and patient safety requirements layered on top of those factors can make healthcare organizations trickier to persuade than customers in other industries.A new Rock Health survey
of 85 digital health founders along with feedback from healthcare organizations offered some useful insights for how digital health entrepreneurs can convert organizations into pilot users and then to paying customers. It also offered a perspective on what prospective customers expect of the entrepreneurs with which they collaborate. Like so many useful insights, some are just common sense.
MADRID (Reuters) – Cancer doctors are widening the net for immunotherapy, a hot new class of drugs that enlist the body’s defenses in the fight against tumors. The latest research shared with 23,000 experts at Europe’s top oncology meeting shows how medicines that have already delivered durable benefits in metastatic disease can also work well at an earlier stage. The findings promise to expand the market for established immuno-oncology (I-O) drugs from companies like Merck, Bristol-Myers Squibb and Roche, while opening up a window for relative latecomers such as AstraZeneca.
A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013. REUTERS/Vivek Prakash/File Photo
ZURICH/MADRID (Reuters) – Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer on Monday, while a rival treatment from Roche with slipping sales failed in a separate study with a similar patient group. All the medicines were tested in melanoma patients who had undergone surgery to cut out tumors and had a genetic mutation called BRAF, making them likely to respond to the targeted cancer pills. Patients with BRAF mutations constitute around half of the melanoma population. Novartis’s mix of Tafinlar and Mekinist slashed the risk of melanoma returning or death by 53 percent versus placebo in patients with stage III disease, according to data released at the European Society for Medical Oncology Congress in Madrid. “These are the best results ever shown for an adjuvant (post-surgery) treatment in stage III melanomas,” said Axel Hauschild of the University of Kiel, Germany, one of the main researchers on the Novartis trial. “These are practice-changing results.”